PlusPlus Lifesciences bags patent for Multi Micronutrient – 3 stage course for pregnancy

IMT News Desk
IMT News Desk
· 3 min read

The patent has allowed for a nationwide launch and distribution of the product

In a recent milestone, Surbhi Gupta and Sameer Agarwal of PlusPlus Lifesciences were granted a patent from the Patent Office of the Government of India for their three-stage Multi-Micronutrient (MMN) supplement called ‘Trimacare’. The patent has allowed for a nationwide launch and distribution of the product.

Trimacare is a supplement based on the MMN model of medication. This model combines traditional nutrients such as iron, folic acid, and Calcium with other essential vitamins and minerals like iodine, zinc, Omega-3, fatty acids, Vitamins A, B, and D, among others, that are necessary for the health of pregnant women throughout all trimesters and the child’s prenatal and long-term health.

The MMN model of medication helps promote maternal health, improve birth weight, and reduce the risk of preterm birth by providing essential nutrients to the body. MMN supplements are also effective in improving childhood survival, growth, body composition, blood pressure, and respiratory and cognitive outcomes. Moreover, they are more effective against medical anaemia compared to traditional prescriptions.

Multi-micronutrients are the building blocks of life and an essential element for pregnant women. One in two pregnant women in India have micronutrient deficiencies. While their diet is rich in carbohydrates, it lacks the essential elements needed for a mother’s and baby’s health and sustenance.

Trimacare is India’s most sophisticated pregnancy supplement. It is a comprehensive solution as it includes 20+ critical micronutrients such as L-Methylfolate, Iro56n, Zinc, Omega-3 and other vitamins and nutrients required for pregnancy. Furthermore, the Omega 3 source is plant-based, making Trimacare suitable for vegetarian and vegan patients.

Trimacare is a 3-stage course designed to provide optimal care for pregnant women and their babies. T1 is prescribed for the first trimester, T2 for the second, and T3 for the third trimester. Each unique formulation is tailored to meet the needs of the mother and the child during that particular trimester. Trimacare is specifically designed to promote brain and organ development in babies while reducing maternal symptoms. It is an easy-to-consume, one-stop solution that provides an effective remedy for expecting mothers. It is particularly helpful for the 40 per cent of women who often find it challenging to comply with therapy during pregnancy due to the typical requirement of taking seven to eight different medications.

Trimacare has introduced several innovations to improve the experience of women taking supplements. For instance, the timely release of iron reduces gastrointestinal side effects, such as bloating and constipation. Additionally, L-methylate is better absorbed by Indian women than Folic Acid, making it an important nutrient for the baby’s natural tube development. Trimacare is formulated with the needs of women and children in mind, using advanced salts that are vegetarian and of the highest quality standard and efficacy.

Speaking about the grant of the patent, Dr Raj Kamal Agarwal, President, of PlusPlus Lifesciences, said, “We are glad to have been granted the patent for Trimacare, a transformative formulation in the field of medicine. It is based on the Multi-Micronutrient model of medication and includes more than 20 nutrients and a unique formulation for each trimester. It is prepared with plant-based sources to cater to evolving lifestyles and eating habits. We look forward to launching Trimacare and making it available nationwide and accessible to every expectant mother, ensuring they achieve optimal prenatal health.”

Experts agree that healthy and balanced maternal nutrition is the key to a healthier pregnancy and better in terms of foetal development and maternal health.

 

Read Next

Annora Pharma Expands Collaboration with AI-Native Traceability Platform AltiusHub to Strengthen Global Drug Traceability
News
May 18, 2026

Annora Pharma Expands Collaboration with AI-Native Traceability Platform AltiusHub to Strengthen Global Drug Traceability

Annora Pharma, the formulations subsidiary of Hetero Group, has expanded its collaboration with AltiusHub. The company is deploying AltiusHub’s AI-native serialization, track & trace and regulatory compliance platform across its export operations. The deployment is designed to improve serialization efficiency by up to 45%. It will also strengthen operational visibility across Annora Pharma’s global supply […]
Article by: IMT News Desk
WFNS Innovation & Technology Committee Announces Partnership with Time Medical International Ventures (India) Pvt Ltd for First-in-Class Medical Technology Innovation
News
May 18, 2026

WFNS Innovation & Technology Committee Announces Partnership with Time Medical International Ventures (India) Pvt Ltd for First-in-Class Medical Technology Innovation

The World Federation of Neurosurgical Societies (WFNS) Innovation & Technology Committee has announced collaboration with Time Medical International Ventures (India) Pvt. Ltd (Time Medical India)., a wholly owned subsidiary of Fischer Medical Ventures Limited, marking a significant milestone in advancing innovation in global neurosurgical care. This marks the first time the Committee has formally partnered […]
Article by: IMT News Desk
National AI Doctors Mission launches in New Delhi: How AI will change Indian healthcare
News
May 18, 2026

National AI Doctors Mission launches in New Delhi: How AI will change Indian healthcare

The National AI Doctors Mission (NAIDM) has been formally launched in New Delhi, marking a major step toward integrating artificial intelligence into everyday clinical practice across India’s public and private healthcare system. The initiative, led by Medical Dialogues in collaboration with the National Medical Forum, aims to make AI “useful and usable” for frontline doctors rather than […]
Article by: IMT News Desk
Gland Pharma rallies on upbeat Q4; profit soars 97% YoY to ₹367 crore
News
May 18, 2026

Gland Pharma rallies on upbeat Q4; profit soars 97% YoY to ₹367 crore

Gland Pharma shares extended gains in the capital markets after the company posted a standout Q4 performance, with consolidated net profit jumping 97% year‑on‑year to ₹367 crore, riding on a sharp improvement in operating leverage and a strong base‑business showing in the US. Revenue for the quarter rose 22% YoY to ₹1,743 crore, while EBITDA surged 48% YoY […]
Article by: IMT News Desk